|
Market Closed -
London S.E.
11:35:22 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 570.00 GBX | -2.56% |
|
+0.71% | -0.35% |
| 10-19 | Cora Gold shareholder Eagle Eye restructures holding | AN |
| 10-19 | Hemogenyx Pharmaceuticals Partners with Nitto Denko to Explore CAR mRNA's Lipid Nanoparticle Delivery | MT |
Company Valuation: Hemogenyx Pharmaceuticals Plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 41.85 | 18.37 | 12.98 | 27.04 | 14.19 | 34.56 |
| Change | - | -56.1% | -29.33% | 108.28% | -47.51% | 143.47% |
| Enterprise Value (EV) 1 | 41.66 | 11.54 | 13.87 | 28.74 | 16.66 | 34.97 |
| Change | - | -72.3% | 20.21% | 107.16% | -42.03% | 109.96% |
| P/E | -19.2x | -2.85x | -3.26x | -3.88x | -2.38x | -2.6x |
| PBR | 47x | 2.24x | 3.96x | 9.59x | 15.8x | 28.9x |
| PEG | - | -0.1x | 0.1x | -0.1x | 0.1x | -0.1x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -20x | -4.42x | -3.55x | -5.39x | -3.24x | -5.16x |
| EV / EBIT | -19.4x | -4.27x | -3.47x | -5.17x | -3.1x | -5.02x |
| EV / FCF | -37.9x | -3.72x | -5.79x | -7.55x | -8.49x | -10.5x |
| FCF Yield | -2.64% | -26.9% | -17.3% | -13.3% | -11.8% | -9.52% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -2.008 | -2.635 | -1.625 | -2.37 | -1.702 | -2.197 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -2.081 | -2.613 | -3.908 | -5.333 | -5.147 | -6.784 |
| EBIT 1 | -2.15 | -2.703 | -3.998 | -5.559 | -5.377 | -6.973 |
| Net income 1 | -2.082 | -5.099 | -3.979 | -6.691 | -5.619 | -9.76 |
| Net Debt 1 | -0.1842 | -6.831 | 0.8901 | 1.698 | 2.464 | 0.4178 |
| Reference price 2 | 38.600 | 7.500 | 5.300 | 9.200 | 4.050 | 5.720 |
| Nbr of stocks (in thousands) | 1,084 | 2,449 | 2,449 | 2,939 | 3,505 | 6,041 |
| Announcement Date | 5/28/21 | 6/8/22 | 6/2/23 | 4/24/24 | 4/25/25 | 4/30/26 |
1GBP in Million2GBP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 53.59M | |
| 18.32x | 6.97x | 13.35x | 1.63% | 69.4B | |
| 30.72x | 8.25x | 27.72x | 0.05% | 57.24B | |
| 39.18x | 6.93x | 20.69x | 0.83% | 57.62B | |
| 34.57x | 3.29x | 14.19x | -.--% | 43.65B | |
| 51.08x | 5.91x | 32.37x | -.--% | 44.03B | |
| -18.44x | 177.78x | -19.56x | -.--% | 38.08B | |
| 36.57x | 9x | 23.45x | 0.36% | 36.31B | |
| 44.16x | 7.87x | 26.34x | -.--% | 32.61B | |
| 29.41x | 6.22x | 16.14x | -.--% | 25.47B | |
| Average | 29.51x | 25.80x | 17.19x | 0.32% | 40.45B | |
| Weighted average by Cap. | 29.33x | 22.92x | 17.62x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SILF Stock
- Valuation Hemogenyx Pharmaceuticals Plc
Select your edition
All financial news and data tailored to specific country editions
